Premium
IMMUNOHISTOCHEMICAL ASSAY FOR OESTROGEN RECEPTORS IN PARAFFIN WAX SECTIONS OF BREAST CARCINOMA USING A NEW MONOCLONAL ANTIBODY
Author(s) -
HUANG AIHUA,
PETTIGREW NORMAN M.,
WATSON PETER H.
Publication year - 1996
Publication title -
the journal of pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.964
H-Index - 184
eISSN - 1096-9896
pISSN - 0022-3417
DOI - 10.1002/(sici)1096-9896(199610)180:2<223::aid-path635>3.0.co;2-h
Subject(s) - concordance , monoclonal antibody , immunohistochemistry , medicine , antigen retrieval , breast carcinoma , immunostaining , pathology , carcinoma , antibody , antigen , breast cancer , cancer , immunology
The aim of this study was to evaluate the utility of a new monoclonal antibody (AER311) that targets the oestrogen receptor (ER) in an immunohistochemical assay (IHA) applied to breast cancers. Ninety‐seven cases of invasive ductal carcinoma were studied by AER311‐IHA using a pressure‐cooking antigen retrieval technique applied to formaldehyde‐fixed, paraffin‐embedded tissue sections; immunostaining was assessed by semi‐quantitative scoring ( H score). There was 80 per cent concordance between the ER status measured by dextran‐coated charcoal (DCC) assay and AER311‐IHA, with 63/97 (65 per cent) tumours positive and 15/97 (15 per cent) tumours negative by both assays. Of the 12 DCC‐positive cases that were negative by AER311‐IHA, 11 were borderline positive (3–8 fmol/mg). Similarly, six of seven DCC‐negative cases that scored positive by AER311‐IHA had only borderline positive H scores (<50). When AER311‐IHA was compared with 1D5‐IHA, there was good concordance in ER status (77 per cent) and a significant correlation ( r =0·7, P <0·001) between H scores. Nevertheless, the correlation between ER level determined by AER311‐IHA and that measured by DCC ( r =0·53, P <0·001) was higher than that for 1D5‐IHA ( r =0·32, P =0·002). AER311‐IHA can therefore provide reliable information about the ER status of breast carcinoma on paraffin sections and is an acceptable alternative to other commercially available monoclonal antibodies.